Case report: Oxaliplatin-induced idiopathic non-cirrhotic portal hypertension: a case report and literature review

Oxaliplatin has become a widely used agent in neoadjuvant chemotherapy for gastrointestinal tract tumors and is an integral part of the therapeutic approach for managing colorectal cancer recurrences and metastases, resulting in a more favorable prognosis for patients. Nevertheless, oxaliplatin can...

Full description

Bibliographic Details
Main Authors: Jiayuan Ye, Yilian Xie, Yaojiang Xu, Nan Chen, Yifei Tu
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Medicine
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1285064/full
_version_ 1797449276583837696
author Jiayuan Ye
Yilian Xie
Yaojiang Xu
Nan Chen
Yifei Tu
author_facet Jiayuan Ye
Yilian Xie
Yaojiang Xu
Nan Chen
Yifei Tu
author_sort Jiayuan Ye
collection DOAJ
description Oxaliplatin has become a widely used agent in neoadjuvant chemotherapy for gastrointestinal tract tumors and is an integral part of the therapeutic approach for managing colorectal cancer recurrences and metastases, resulting in a more favorable prognosis for patients. Nevertheless, oxaliplatin can give rise to idiopathic non-cirrhotic portal hypertension (INCPH). The emergence of INCPH can disrupt tumor chemotherapy and incite persistent adverse reactions in later stages, significantly complicating clinical management. Consequently, we have presented a case report of INCPH induced by oxaliplatin chemotherapy with the aim of advancing the diagnosis and treatment of this condition, with a particular focus on the clinical manifestations. This study has ascertained that the condition is primarily attributed to complications related to portal hypertension, such as gastrointestinal bleeding, splenomegaly, and hypersplenism. The pathological features primarily involve hepatic sinus dilation and congestion, portal obstruction, absence, stenosis, shunting, localized venous and perisinusoidal fibrosis, as well as hepatocellular atrophy. Treatment primarily concentrates on strategies typically employed for cirrhosis. Endoscopic ligation, sclerotherapy, and non-selective beta-blockers (NSBBs) can be selected to prevent and treat variceal hemorrhage. Transjugular intrahepatic portosystemic shunt (TIPS) and liver transplantation can also be chosen for severe cases. Notably, despite the timely discontinuation of oxaliplatin, most patients continue to experience disease progression, ultimately resulting in a poor prognosis due to either tumor advancement or the ongoing progression of portal hypertension. This emphasizes the importance for physicians to be aware of and consider the risk of INCPH when prescribing oxaliplatin.
first_indexed 2024-03-09T14:23:30Z
format Article
id doaj.art-489c74736c21433187fc9dfed9fcc6f8
institution Directory Open Access Journal
issn 2296-858X
language English
last_indexed 2024-03-09T14:23:30Z
publishDate 2023-11-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Medicine
spelling doaj.art-489c74736c21433187fc9dfed9fcc6f82023-11-28T08:39:17ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2023-11-011010.3389/fmed.2023.12850641285064Case report: Oxaliplatin-induced idiopathic non-cirrhotic portal hypertension: a case report and literature reviewJiayuan Ye0Yilian Xie1Yaojiang Xu2Nan Chen3Yifei Tu4Department of Infectious Diseases, Shangyu People's Hospital of Shaoxing, Shaoxing, Zhejiang, ChinaDepartment of Infectious Diseases, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, ChinaDepartment of Infectious Diseases, Shangyu People's Hospital of Shaoxing, Shaoxing, Zhejiang, ChinaDepartment of Infectious Diseases, Shangyu People's Hospital of Shaoxing, Shaoxing, Zhejiang, ChinaDepartment of Radiology, Shangyu People's Hospital of Shaoxing, Shaoxing, Zhejiang, ChinaOxaliplatin has become a widely used agent in neoadjuvant chemotherapy for gastrointestinal tract tumors and is an integral part of the therapeutic approach for managing colorectal cancer recurrences and metastases, resulting in a more favorable prognosis for patients. Nevertheless, oxaliplatin can give rise to idiopathic non-cirrhotic portal hypertension (INCPH). The emergence of INCPH can disrupt tumor chemotherapy and incite persistent adverse reactions in later stages, significantly complicating clinical management. Consequently, we have presented a case report of INCPH induced by oxaliplatin chemotherapy with the aim of advancing the diagnosis and treatment of this condition, with a particular focus on the clinical manifestations. This study has ascertained that the condition is primarily attributed to complications related to portal hypertension, such as gastrointestinal bleeding, splenomegaly, and hypersplenism. The pathological features primarily involve hepatic sinus dilation and congestion, portal obstruction, absence, stenosis, shunting, localized venous and perisinusoidal fibrosis, as well as hepatocellular atrophy. Treatment primarily concentrates on strategies typically employed for cirrhosis. Endoscopic ligation, sclerotherapy, and non-selective beta-blockers (NSBBs) can be selected to prevent and treat variceal hemorrhage. Transjugular intrahepatic portosystemic shunt (TIPS) and liver transplantation can also be chosen for severe cases. Notably, despite the timely discontinuation of oxaliplatin, most patients continue to experience disease progression, ultimately resulting in a poor prognosis due to either tumor advancement or the ongoing progression of portal hypertension. This emphasizes the importance for physicians to be aware of and consider the risk of INCPH when prescribing oxaliplatin.https://www.frontiersin.org/articles/10.3389/fmed.2023.1285064/fulloxaliplatinvariceal bandingidiopathic non-cirrhotic portal hypertensiongastrointestinal tumorscase report
spellingShingle Jiayuan Ye
Yilian Xie
Yaojiang Xu
Nan Chen
Yifei Tu
Case report: Oxaliplatin-induced idiopathic non-cirrhotic portal hypertension: a case report and literature review
Frontiers in Medicine
oxaliplatin
variceal banding
idiopathic non-cirrhotic portal hypertension
gastrointestinal tumors
case report
title Case report: Oxaliplatin-induced idiopathic non-cirrhotic portal hypertension: a case report and literature review
title_full Case report: Oxaliplatin-induced idiopathic non-cirrhotic portal hypertension: a case report and literature review
title_fullStr Case report: Oxaliplatin-induced idiopathic non-cirrhotic portal hypertension: a case report and literature review
title_full_unstemmed Case report: Oxaliplatin-induced idiopathic non-cirrhotic portal hypertension: a case report and literature review
title_short Case report: Oxaliplatin-induced idiopathic non-cirrhotic portal hypertension: a case report and literature review
title_sort case report oxaliplatin induced idiopathic non cirrhotic portal hypertension a case report and literature review
topic oxaliplatin
variceal banding
idiopathic non-cirrhotic portal hypertension
gastrointestinal tumors
case report
url https://www.frontiersin.org/articles/10.3389/fmed.2023.1285064/full
work_keys_str_mv AT jiayuanye casereportoxaliplatininducedidiopathicnoncirrhoticportalhypertensionacasereportandliteraturereview
AT yilianxie casereportoxaliplatininducedidiopathicnoncirrhoticportalhypertensionacasereportandliteraturereview
AT yaojiangxu casereportoxaliplatininducedidiopathicnoncirrhoticportalhypertensionacasereportandliteraturereview
AT nanchen casereportoxaliplatininducedidiopathicnoncirrhoticportalhypertensionacasereportandliteraturereview
AT yifeitu casereportoxaliplatininducedidiopathicnoncirrhoticportalhypertensionacasereportandliteraturereview